3-Aminopiperidine-2,6-Dione Hydrochloride CAS 24666-56-6;2686-86-4 Purity >99.0% Lenalidomide Intermediate Factory
Ruifu Chemical ke moetsi ea ka sehloohong oa 3-Aminopiperidine-2,6-Dione Hydrochloride (CAS: 24666-56-6; 2686-86-4) e nang le boleng bo phahameng, bohareng ba Pomalidomide (CAS: 19171-19-8).Ruifu Chemical e ka fana ka lits'ebeletso tsa lefats'e ka bophara, theko ea tlholisano, litšebeletso tse ntle haholo, tse nyane le tse ngata tse fumanehang.Reka 3-Aminopiperidine-2,6-Dione Hydrochloride, Please contact: alvin@ruifuchem.com
| Lebitso la Lik'hemik'hale | 3-Aminopiperidine-2,6-Dione Hydrochloride |
| Litlhaloso tse tšoanang | 3-Aminopiperidine-2,6-Dione HCl;3-Amino-2,6-Piperidinedione Hydrochloride;2,6-Dioxopiperidine-3-Ammonium Chloride |
| Nomoro ea CAS | 24666-56-6 |
| CAS e amanang le eona | 2686-86-4;25181-50-4 |
| Boemo ba Setoko | Ka Setokong, Sekhahla sa Tlhahiso Ho fihlela ho Lithane |
| Foromo ea limolek'hule | C5H9ClN2O2 |
| Boima ba Molek'hule | 164.59 |
| Melting Point | 120 ℃ |
| COA & MSDS | E fumaneha |
| Tšimoloho | Shanghai, China |
| Brand | Ruifu Chemical |
| Ntho | Litlhaloso |
| Ponahalo | Phofo ea Crystalline e Ntle-Bosoeu |
| Mokhoa oa Bohloeki / Analysis | >99.0% (HPLC) |
| Mongobo (KF) | <0.50% |
| Tahlehelo ka ho Omisa | <0.50% |
| Masalla a ho Ignition | <0.20% |
| Litšila ka Kakaretso | <1.00% |
| Infrared Spectrum | E Ikamahanya le Sebopeho |
| Tekanyetso ea Teko | Maemo a Khoebo |
| Tšebeliso | Bohareng ba Lenalidomide (CAS: 191732-72-6) |
Sephutheloana: Botlolo, Aluminium foil bag, 25kg/Cardboard Drum, kapa ho ea ka tlhokahalo ea moreki.
Boemo ba polokelo:Boloka ka lijaneng tse koetsoeng sebakeng se phodileng le se omileng;Sireletsa leseli le mongobo
3-Aminopiperidine-2,6-Dione Hydrochloride (CAS: 24666-56-6; 2686-86-4) ke bohareng ba ho lokisetsa Lenalidomide (CAS: 191732-72-6).Lenalidomide ke mofuta oa litlhare tsa antitumor tse hlahisitsoeng ke lik'hamphani tsa Amerika tsa bioloji tsa meriana.E na le mesebetsi e mengata e kang anti-tumor, regulation ea 'mele ea ho itšireletsa mafung le anti-angiogenesis.E ka thibela secretion ea inflammatory cytokines, 'me eketsa secretion ea peripheral blood mononuclear anti-inflammatory cytokines.E ka thibela kholo ea lisele tse ngata tsa myeloma le MM1S cell.Lithuto tsa kliniki tse laoloang ka makhetlo a mabeli tse sa boneng ka makhetlo a mabeli li hlahloba tšireletso le phello ea phekolo ea lenalidomide e sebelisetsoang myeloma e mengata.Liphetho tsa morao-rao tsa lipatlisiso tsa kliniki li bontša hore lenalidomide ha e na phello ea pholiso feela ea ho phekola MDS le MM, empa hape le ho phekola myeloma, leukemia, metastatic renal cell carcinoma, tumor e tiileng, idiopathic generalized amyloidosis le systemic bone marrow fibrosis lefu le nang le moko o sa butsoang.Ka Tšitoe 2005, US Food and Drug Administration (FDA) e ile ea amohela lenalidomide hore e sebelisoe kalafong ea myelodysplastic syndrome (MDS).
